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ABSTRACT
Diabetic foot ulcers (DFUs) are a major health problem as the number 
of patients continues to increase, are difficult to heal, require enormous 
management costs, and deteriorate the quality of life of patients, their families 
and societies. The pathogenesis of DFUs is complex. Most important factors 
that increase the risk of DFUs are peripheral neuropathy, foot deformities, 
frequent minor trauma, and peripheral arterial disease. Neuropeptides 
derangement, hypoxia, hyperglycemia, and infection act as the cause of 
chronicity of DFUs. Therefore, during the initial evaluation of DFU, patients 
need to be checked for their metabolic status, presence or absence of peripheral 
neuropathy, vascular insufficiency, foot deformities, and infection of the ulcer 
and its underlying bone. Then, DFUs are classified by the severity of vascular 
insufficiency, the depth of the wound, and the severity of the infection. This 
classification system helps clinicians to determine whether the patient needs 
to be hospitalized or amputated and helps to establish DFU management 
strategies. In the management of DFUs, adequate blood flow to the wound 
area should be achieved. Glycemic control and standard wound care should be 
encouraged. Standard wound care includes debridement, offloading, wound 
moisture balance with suitable dressing, edema control, and infection control. 
Education about preventive foot care should be taught to the patients and 
their families. As the pathogenesis and management of DFUs are complex, a 
multidisciplinary team consists of expert individuals in their respective fields 
should be involved.
ABSTRAK
Ulkus kaki diabetik (UKD) masih merupakan masalah dalam bidang kesehatan 
karena jumlahnya terus meningkat, sulit disembuhkan, membutuhkan biaya 
penanganan yang besar, dan dapat memperburuk kualitas hidup pasien beserta 
keluarga dan masyarakat sekitarnya. Patogenesis UKD sangat kompleks. 
Faktor terpenting yang meningkatkan risiko terjadinya UKD adalah neuropati 
perifer, deformitas kaki, seringnya terjadi trauma minor pada kaki, dan 
penyakit arterial perifer. Gangguan neuropeptida, hipoksia, hiperglikemia, dan 
infeksi berperan sebagai penyebab UKD menjadi kronis. Oleh karena itu, pada 
evaluasi awal pasien dengan UKD perlu diperiksa mengenai status metabolik 
pasien, ada tidaknya neuropati perifer, insufisiensi vaskular, deformitas kaki, 
dan infeksi pada ulkus maupun tulang di bawahnya. Selanjutnya, pasien UKD 
diklasifikasikan berdasarkan keparahan insufisiensi vaskular, kedalaman 
luka, dan keparahan infeksinya. Sistem klasifikasi ini membantu menentukan 
apakah pasien perlu dirawat inap atau diamputasi dan membantu membuat 
strategi penatalaksanaan UKD. Dalam penatalaksanaan UKD, aliran darah ke 
daerah luka perlu diusahakan agar adekuat. Kontrol glikemik dan perawatan 
luka standar juga perlu adekuat. Perawatan luka standar meliputi debridement, 
offloading, menjaga kelembapan luka dengan bahan balut yang sesuai, kontrol 
edema, dan kontrol infeksi. Edukasi tentang perawatan kaki perlu diajarkan 
pada pasien dan keluarganya. Tim yang terdiri dari individu-individu ahli 
dalam bidangnya masing-masing diperlukan untuk menangani UKD mengingat 
kompleksitas faktor yang terlibat dalam patogenesis dan tatalaksananya. 
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INTRODUCTION
Diabetic foot ulcer (DFU) is defined 
as an ulcer affected the foot of a diabetic 
patient that associated with peripheral 
neuropathy and/or arterial disease.1,2 It is 
a chronic and devastating complication 
of diabetes.1,3 Only two-thirds of foot 
ulcers heal, while the rest of them will 
remain active.4 Within 6–18 months after 
initial evaluation, 5–24% of DFU cases 
will end in limb amputation.1
Diabetic foot ulcers are common 
worldwide, although its frequency and 
severity vary from region to region.4 A 
previous study has found that the global 
prevalence of DFU was 6.3%, while in 
Asia it was 5.5%.3 The incidence of DFU 
has increased due to the increasing 
worldwide prevalence of DM in all age-
groups.3,5 The lifetime risk for developing 
foot ulcer in a diabetic patient is 15–
25%.1,6 Based on gender and type of DM, 
DFUs are more prevalent in male (4.5%) 
than female (3.5%) and in patients with 
type 2 DM (6.4%) than in patients with 
type 1 (5.5%).3 Indonesia ranks fourth 
in the list of countries with the highest 
numbers of estimated cases of DM for the 
year 2000 and 2030.5 Ministry of Health, 
Republic of Indonesia has reported that 
the proportion of DM in ≥ 15 years age-
groups in Indonesia in 2013, based on 
blood glucose examination, was 6.9%. 
There were 54.0% foot neuropathy, 
10.9% peripheral arterial disease, 8.7% 
foot ulcer, and 1.3% amputation in 
RSUP Dr. Cipto Mangunkusumo Jakarta 
(RSCM), which were reported as the 
complications of DM in 2011.7 
Diabetic foot ulcers present as a 
major burden in economic.6 As much as 
one third of $176 billion is spent annually 
for lower-extremity–related diabetes 
care in the United States.8 Aside than that, 
foot ulcers adversely affect the quality 
of life of the patients, their families, 
and society because of the frequent 
recurrence and limb amputation.6 
Previous study found that about 40% of 
patients had a recurrence within 1 year 
after the ulcers heal, almost 60% within 
3 years, and 65% within 5 years.8 Foot 
ulcers, which subsequently deteriorate 
to severe infection or gangrene, precede 
about 85% of all amputations in diabetic 
patients.2 Indonesia, as the fourth 
countries with the highest numbers of 
diabetes,5 will face the same burden on 
its healthcare system.
Diabetic foot ulcer is multifactorial 
in nature.9 Multidisciplinary approach is 
required to give a proper management.9,10 
Nevertheless, the outcome of 
management of DFUs still remains a 
challenge.11 Combination of detrimental 
effect on patients’ health, major economic 
burden, and unsatisfactory outcome of 
management encourage us to review 
DFUs. This review aimed to provide the 
pathogenesis of DFU, what should be 
done in the initial evaluation of patients 
presenting foot ulcer and how to classify 
DFU, and the recent recommended 
managements for DFUs. 
DISCUSSION
Pathogenesis of DFU
Development of foot ulcer in diabetic 
patients
There are various risk factors for the 
development of foot ulcers in diabetic 
patients. The most important factors are 
peripheral neuropathy, foot deformity, 
minor trauma, and peripheral arterial 
disease.2,12
Up to 66% of diabetic patients 
experience neuropathy in the lower 
extremity.10 It is attributable to 
chronic hyperglycemia exposure.10,13 
Sensorimotor polyneuropathy is the most 
prevalent neuropathy in diabetes.13 The 
sensory neuropathy is associated with 
lack of sensation of injuries; thus the foot 
becomes vulnerable to mechanical or 
pressure or thermal injury.2 Repetitive 
shear stress on an area is the common 
cause of DFUs.8 The motor neuropathy 
triggers atrophy in intrinsic foot and leg 
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muscles. The body becomes unable to 
coordinate movements and the anatomy 
of the foot gradually altered, initiates 
the formation of foot deformities.2,10 
Foot deformities, limited joint mobility 
and lack of sensation result in abnormal 
biomechanical loading of some areas 
of the foot. The skin on that areas 
thicken (callus formation), undergo 
subcutaneous hemorrhage, and finally 
begin to ulcerate.2 Over time, diabetic 
patients may develop autonomic 
dysfunction in the lower extremity. It 
affects the sudomotor and results in foot 
skin dryness. The dry skin is vulnerable 
to crack and ulcerate.13,14 Peripheral 
arterial disease (PAD) causes inadequate 
transfer of oxygen and nutrients to the 
wound area and increases the risk of 
the wound to become chronic and also 
infected.2,10,12,15 
Chronicity of DFU
Cellular components, extracellular 
matrix (ECM), cytokines and growth 
factors coordinate the orderly 
overlapping 4 phases in normal wound 
healing process.4,16,17 Diabetic foot 
ulcer fails to progress through those 
normal phases, hence is susceptible 
to become chronic.10,14,18 Failure 
of the DFU to heal is connected to 
neuropeptides derangement, hypoxia, 
and hyperglycemia. Neuropeptides 
play a role in controlling inflammation, 
angiogenesis, cytokines expression, and 
growth factors release. Neuropeptides 
derangement is linked to the peripheral 
neuropathy. Hypoxia is linked to the 
PAD. Hyperglycemia triggers defective 
response to hypoxia and dysfunctions in 
the diabetic cells and tissues.10,19-21 
Hypoxia in a wound area normally 
induces stability of hypoxia-inducible 
factor (HIF)-1α, a subunit of an 
important transcription factor HIF-1, 
which mediates adaptation response 
of cells to hypoxia.22,23 The stability 
and transactivation function of HIF-
1α is compromised by hyperglycemia 
through several mechanisms, such as 
methylglyoxal and reactive oxygen 
species (ROS).23 As a result, HIF-1 
is degraded and leads to impaired 
hypoxia-induced genes transactivation 
in many cellular components of wound 
healing.23-25 
Defective response of HIF-1 to hypoxia 
triggered by hyperglycemia occurs in 
many cells, including neutrophils and 
macrophages. Impairment of glycolytic 
enzymes genes transactivation and 
expression caused by the degradation of 
HIF-1 result in depletion of intracellular 
adenosine triphosphate (ATP) pools 
in neutrophils and macrophages. 
ATP depletion produces disturbance 
of the inflammatory response of the 
neutrophils and macrophages due to 
decreased aggregation, motility, bacterial 
killing, and invasion.25 Macrophages also 
show inability to phagocytose pathogenic 
organisms and apoptosed neutrophils 
(efferocytosis), which increases the 
number of apoptotic cells in diabetic 
ulcers and inhibits the switch from 
M1 macrophages to M2 macrophages 
phenotype. M1 macrophages generate 
more pro-inflammatory cytokines, 
such as tumor necrosis factor (TNF)-α, 
interleukin (IL)-1, IL-6, as well as 
inducible nitric oxide synthase (iNOS).26-
29 These pro-inflammatory cytokines lead 
to the recruitment of more immune cells, 
resulting in wounds that remain in the 
inflammatory phase and fail to progress 
to the next phase. 
Neutrophils in diabetes have an 
elevated neutrophil extracellular trap 
(NET) components, such as elastase, 
histones, neutrophil gelatinase-
associated lipocalin, and proteinase-3. 
The neutrophils are primed to increased 
spontaneous NETosis, and have an 
impaired NADPH oxidase (NOX)-
independent NETosis.30 Increased NET 
components degrade important growth 
factors, such as platelet derived growth 
factor (PDGF) dan transforming growth 
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factor (TGF)-β. The NET components also 
degrade and inactivate components of 
ECM, elevate matrix metalloproteinases 
(MMPs), and reduce tissue inhibitor 
of metalloproteinases (TIMPs).26-30 The 
imbalance between MMPs and TIMPs 
augments degradation of ECM. The 
ECM breakdown products promote 
inflammation further and create a self-
sustaining process.19-31 The DFUs could 
not progress through the inflammation 
phase.
Extracellular matrix, including 
collagen, is mainly produced by 
fibroblasts. Hyperglycemia alters the 
diabetic fibroblasts phenotype. The 
fibroblasts show decreased collagen 
synthesis ability and low mitogenic 
capacity,32 migrate less,33,34 resistant to 
growth factors such as insulin-like growth 
factor (IGF)-1 and epidermal growth 
factor (EGF),35,36 and decreased ability to 
express VEGF in response to insulin and 
hypoxia.14,37 The decrease in collagen 
synthesis ability is compounded by 
prolonged hypoxia. Prolonged hypoxia, 
is a result of persistent inflammation in 
diabetic wound.24 Since oxygen is reduced 
in hypoxia and the oxygen is needed as a 
substrate in the hydroxylation of proline 
and lysine residues of procollagen, then 
the synthesis and deposition of collagen 
are also reduced.38 Degradation of 
ECM and TGF-β1, caused by persistent 
inflammation in diabetic wound, also 
impair collagen synthesis.19,31,32 As a 
result, fibroblasts are unable to make 
progress in depositing ECM because 
degradation of collagen occurs more 
rapidly than its synthesis. Diabetic 
fibroblasts transdifferentiation to 
myofibroblasts is also impaired. TNF-α, 
secreted by granulocytes, suppresses 
expression of α-smooth muscle actin 
(α-SMA) in diabetic fibroblasts.32,39 
Failure of diabetic fibroblasts to deposit 
optimal ECM and to differentiate into 
myofibroblasts halt the healing of DFUs. 
Endothelial cells (ECs) in diabetic 
ulcers also become dysfunctional 
and susceptible to apoptosis.40 HIF-1 
degradation leads to impaired VEGF and 
angiopoietins (Ang) genes transactivation 
in ECs. VEGF and Ang are the main 
molecular regulators of angiogenesis.15,40 
VEGF is deficit in diabetic ulcers. Deficit 
in VEGF affects wound angiogenesis. ECs 
become less mitogenic and endothelial 
progenitor cells (EPCs) migrate less from 
the bone marrow.41 The EPCs’ capacity 
to produce angiogenic sprouts and tubes 
is reduced in diabetes and it affects the 
baseline vascularity, capillary growth, 
and granulation tissue formation in 
diabetic wound.40 Angiopoietins consist 
of Ang1 and Ang2. In diabetic wounds 
the ratio of Ang1 to Ang2 is decreased. 
The decreased ratio of Ang1 to Ang 
2 implies that the ability of diabetic 
wound vasculature to progress to a 
mature phenotype is disturbed.15,40 
This disturbance in vascular maturity 
progression is understandable because 
Ang1 promotes ECs survival and vascular 
maturation, stabilizes endothelial 
interactions with supporting cells and 
limits the vascular permeability.15 On 
the contrary, Ang 2 has been reported to 
induce ECs migration and proliferation 
and the sprouting of new blood vessels 
in conjunction with VEGF, whereas in 
the absence of VEGF, it induces ECs 
apoptosis and vessel regression.15,40 
Wound angiogenesis impairment in DFUs 
is enhanced by M2 macrophages deficit, 
fibroblasts dysfunction to express VEGF, 
PDGF degradation, and perturbation of 
microRNAs (miRNAs) (e.g. miR26-b, miR-
200b, and  miR27-b).37,40 As angiogenesis 
is impaired, the wound healing process 
will be delayed and  become chronic. 
Keratinocytes form the outer layer 
of the skin. Oxidative stress, induced 
by high glucose, contributes to elevated 
epidermal growth factor receptor (EGFR) 
expression that subsequently resulted in 
enhanced extracellular signal–regulated 
kinase (ERK) signaling and increased IL-8 
production in epidermal keratinocytes. 
Higher level of IL-8 is responsible for 
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recruiting and activating neutrophils. 
Excessive neutrophil infiltration 
contributed to the impaired wound 
healing.42 Keratinocytes in DFUs also 
showed impairment in proliferation, 
migration, and differentiation, apoptosis, 
defective expression of receptors for 
TGF- β, and poor response to growth 
factors. These changes in keratinocytes 
phenotype account for hampered re-
epithelialization and wound closure.32,43 
Pathologic mechanisms in DFU
All of the pathologic response 
and cellular dysfunctions in diabetic 
patients stem from overproduction 
of ROS by the mitochondrial electron-
transport chain. Hyperglycemia 
increases mitochondrial production of 
ROS through inducing intracellular high 
glucose and activating nicotinamide 
adenine dinucleotide phosphate (NAD(P)
H) oxidase by interaction of angiotensin 
II with angiotensin II receptor subtype 
1 (AT1) in target cells.
22,44,45 The ROS 
causes breaks in nuclear DNA strand, 
which then activates poly(ADP-ribose) 
polymerase (PARP). PARP modifies and 
reduces glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) activity. 
Decreased GAPDH activity activates the 
pathologic mechanisms, i.e. increased 
flux of glucose and other sugars 
through the polyol pathway, increased 
intracellular formation of advanced 
glycation end product (AGE) precursor, 
increased expression of AGEs receptor 
and its activating ligands, activation 
of protein kinase C (PKC) isoforms, 
and increased hexosamine pathway 
activity.22,44
Increased polyol pathway flux 
results in diminished amount of reduced 
glutathione (GSH), a pivotal intracellular 
antioxidant. Diminished amount of 
GSH increases susceptibility of cells to 
intracellular oxidative stress, which then 
can damage the cells.22,44
Increased intracellular AGE 
precursors causes intracellular proteins 
modification and alters the function of 
the proteins, especially proteins involved 
in the regulation of gene transcription. 
Intracellular AGE precursors can 
diffuse out of the cell and modify 
extracellular matrix molecules. This 
modification then changes the signaling 
between the matrix and the matrix 
receptors (integrins) on the surface of 
cells and causes cellular dysfunctions. 
Extracellular AGE precursors can modify 
plasma proteins (such as albumin) 
too. Binding of these modified plasma 
proteins to AGE receptors on cells will 
activate the cells, causing the production 
of inflammatory cytokines and growth 
factors and its subsequent pathological 
changes, such as inhibition of HIF-
1α stability, endothelial dysfunction, 
decreased ability of macrophages to 
phagocytose apoptosed neutrophils, and 
functional sensory deficits.22,29,44
Increased AGEs receptor (RAGE) 
and activation by its ligands stimulate 
a host of proinflammatory events and 
promotes chronic inflammation. Such 
chronic inflammation plays a major 
role in the development of diabetic 
complications.22,46
Activation of PKC isoforms changes 
a variety of gene expression. Decreased 
endothelial nitric oxide synthase (eNOS) 
and increased of endothelin-1, VEGF, 
TGF-β, and plasminogen activator 
inhibitor-1 (PAI-1) cause vascular 
pathology.22,44 Activated PKCδ also 
inhibits stimulation of angiogenesis 
and granulation tissue formation by 
fibroblasts.37 Moreover, activated PKC 
plays a role in increasing nuclear factor 
κB (NF-κB), a transcription factor that 
activates many pro-inflammatory genes, 
and NAD(P)H oxidases, which generates 
more ROS.22,44
Increased hexosamine pathway 
activity generates uridine diphosphate 
(UDP) N-acetyl glucosamine. Specific 
O-linked N-acetylglucosamine (O-GlcNac) 
transferases use N-acetyl glucosamine 
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for posttranslational modification of 
specific serine and threonine residues of 
transcription factors. Overmodification 
by this glucosamine results in pathologic 
changes in gene expression. For 
example, increased modification of 
the transcription factor Sp1 results in 
increased expression of TGF-β1 and 
PAI-1, which are bad for diabetic blood 
vessels.22,44
In addition to the pathologic 
changes above, overproduction of ROS 
induced by hyperglycemia can drive 
persistent epigenetic changes, imposing 
a continued activation of the NF-
κB-p65 and downstream inflammatory 
promoters. Diabetic individuals will 
have to afford a continuous deregulation 
of the inflammatory homeostasis and 
superoxide metabolism pathways.47 This 
“systemic inflammation” disrupts the 
insulin receptor-mediated anabolism 
via NF-κB and c-Jun N-terminal kinases 
systems pathways activation. Epigenetic 
changes contribute to the formation 
of diabetic complications, including 
impaired diabetic wound healing.48 
Formation of biofilms by the bacterial 
communities is another factor which 
leads to the chronicity of DFU.10 The 
communities of bacteria in the biofilms 
secrete a matrix or glycocalyx, which 
is protective against the host immune 
response and eradication. Continuously 
present bacteria cause inflammation, 
which leads to the release of proteases 
and ROS from the inflammatory cells. 
These inflammatory cells’ products, 
together with the exotoxins and proteases 
secreted by the bacteria degrade proteins 
that are essential for healing.10,14
After discussing the interconnected 
factors and the complexity of the 
pathogenesis of DFUs, it is understandable 
that the DFU’s management is still a 
challenge. Ideally, all the factors in the 
pathogenesis must be well managed to 
obtain a good result. Hereafter, initial 
evaluation, classification, and recent 
management of DFUs will be discussed. 
Risk factors for a diabetic patient to 
develop foot ulcer and for the ulcer 
to become chronic and the pathologic 
mechanisms caused by hyperglycemia 
should be kept in consideration while 
evaluating and treating the DFUs.
Initial evaluation for DFU patients
A thorough evaluation of ulcer 
characteristics should be done initially. 
Plantar surfaces and sites of repetitive 
trauma and increased pressure should 
not be overlooked because they are 
the most common site of DFUs.10,14 
Clinicians should evaluate the depth, 
size, and border of the ulcer. The ulcer 
may be associated with callus, foot 
deformity, or limited joint mobility; 
pink, warm, and dry skin; signs of skin 
fissures and breakdown; and distal 
anesthesia or paraesthesia.14 As well as 
the characteristics of the ulcer, clinicians 
should remember to evaluate a DFU 
patient as a whole. The metabolic status, 
the presence of neuropathy and vascular 
insufficiency on the affected foot or limb, 
foot deformities (e.g. claw toes, hammer 
toes), and the presence of infection in 
the ulcer should be assessed too because 
those are the risk factors for chronic 
nonhealing DFU.12 Poor clinical outcomes 
are generally associated with PAD, 
deepening of the wound, and presence of 
infection in the ulcer.10 Early detection of 
risk factors and appropriate treatments 
of patients with poor ulcer healing may 
prevent up to 85% of amputations.49
Symptoms of neuropathy, such 
as tingling or pain in the lower limb, 
especially at night, should be asked. 
Sensory foot examination to detect 
neuropathy should be done. Pressure 
perception can be assessed by using the 
10-g Semmes-Weinstein monofilament; 
vibration perception by applying tuning 
fork (128 Hz) on a bony part on the 
dorsum of distal phalanx of the first 
toe; discrimination by pin prick test on 
dorsum of foot, without penetrating the 
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skin; tactile sensation by applying cotton 
wisp on dorsum of foot; and reflexes by 
assessing Achilles tendon reflexes.50,51
Evaluating the presence of vascular 
insufficiency can be conducted through 
a range of non-invasive vascular tests. 
These include ankle-brachial index 
(ABI), toe-brachial index, toe systolic 
blood pressure, transcutaneous oxygen 
pressure (TcPO2), ankle peak systolic 
velocity, hyperspectral imaging, 
microvascular oxygen saturation, and 
skin perfusion pressure.2,14,49 A systematic 
review and meta-analysis of those tests 
had found that most of the available 
evidence evaluated only TcPO2 and 
ABI. TcPO2 was more reliable to predict 
wound healing and limb amputation 
than ABI, but further research was 
needed to provide higher effectiveness 
evidence.49 When non-invasive 
diagnostic is indicated to decide the 
needed treatment of the arterial lesions, 
vascular imaging may be helpful. The 
vascular imaging tests include duplex 
ultrasonography, computed tomography 
angiography (CTA), magnetic resonance 
angiography (MRA), and digital 
subtraction angiography (DSA).2,14 Choice 
of imaging method is influenced by the 
presence of renal insufficiency in the 
patients, because contrast media are 
nephrotoxic agents.2
The presence and severity of 
ulcer’s infection and the wound depth 
(involvement of the bone) should be 
defined at initial evaluation too.10,12 
Infection is present if there are at least two 
local findings of inflammation. The signs 
of inflammation are redness (erythema 
or rubor), warmth (color), pain or 
tenderness (dolor), induration (swelling 
or tumor) and purulent secretions. When 
inflammatory signs are diminished 
because of peripheral neuropathy or 
ischemia, other features (sometimes 
called secondary) suggestive of infection 
may be helpful. Those secondary features 
include the presence of necrosis, friable 
or discolored granulation tissue, non-
purulent secretion, foetid odor or the 
failure of a properly treated wound 
to heal.12 Vital signs and appropriate 
blood tests examinations (i.e. 
erythrocyte sedimentation rate, blood 
leukocyte count, C-reactive protein, and 
procalcitonin), wound debridement, 
probing and assessing the depth and 
extent of the ulcer are necessary to 
evaluate the severity of the infection 
and to diagnose osteomyelitis.12,14 Plain 
radiography, magnetic resonance 
imaging (MRI), white blood cell-labelled 
radionuclide scan, combined single-
photon emission computed tomography 
and computed tomography (SPECT/
CT) or fluorine-18-fluorodeoxyglucose 
positron emission tomography (PET) 
scans, may be useful to improve the 
diagnostic accuracy of osteomyelitis.2,12 
However, the criterion standard for 
diagnosing osteomyelitis remains a 
culture of the bone and, when possible, 
histopathological examination.12,52
Properly obtained deep tissue 
specimens for Gram stain and culture, to 
determine the causative microorganisms 
and their antibiotic sensitivity, are 
advised in initial evaluation of patients 
with infected DFU prior to starting 
empirical antibiotic therapy.2,12 Mild 
(superficial and limited) infection is 
usually caused by aerobic Gram-positive 
cocci, especially Staphylococcus aureus. 
Chronic infections and more severe 
infections are often polymicrobial 
with aerobic Gram-negative rods and 
anaerobes.2,10,50,52 In the past decade, 
molecular techniques provide powerful 
means to define chronic wound microbial 
communities.10
Classification systems for DFUs
After the initial evaluation, 
clinicians should classify the DFU. 
Proper classification of the DFU is very 
important in predicting the need for 
hospitalization or lower extremity 
amputation and in planning strategies 
for treatment of diabetic foot lesions.10,12 
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Various classification systems have 
been proposed to assess the severity of 
diabetic foot lesion, including PEDIS 
(perfusion, extent/size, depth/tissue loss, 
infection, sensation), UTSA (University of 
Texas Antonio), Wagner–Meggit, Brodsky 
Depth–Ischemic, and Saint Elian.10,53,54 
No system has accepted unequivocal. 
In line with the risk factors that cause 
poor clinical outcomes, there are three 
classification systems that incorporate 
ischemia, wound depth, and infection 
into their assessment criteria. The three 
classification systems will be discussed 
below.
The PEDIS system was originally 
developed by the International Working 
Group on the Diabetic Foot (IWGDF) 
for research purposes. The aims of the 
classification system are to facilitate 
communication and enable the 
comparison of the results of different 
research projects.53 However, it can serve 
as a clinical classification as well. In 
PEDIS system, perfusion in the affected 
foot, extent/size of the ulcer, depth/tissue 
loss of the ulcer, symptoms and signs of 
infection, and sensation on the affected 
foot are graded. The higher grade 
shows the more severe of the ulcer. This 
classification has been shown in several 
prospective studies to predict the need 
for hospitalization or lower extremity 
amputation.12
The University of Texas Antonio 
classification system (UTSA) is now 
widely used in various clinical trials 
and diabetic centers (Table 1). In this 
system grading, the basis of depth of 
the lesion and stages are classified on 
presence of ischemia, wound bioburden 
or combination of both. There are grades 
(0–3) and stages (A–D). Wounds of higher 
grade or stages are more prone to a lower 
extremity amputation.10
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In response to the increasing 
number of diabetic patients with critical 
limb ischemia, the Society for Vascular 
Surgery proposed a new classification 
scheme that combines the classification 
schemes based on PAD perfusion 
patterns with foot ulcer schemes. The 
new classification system is titled WIfI 
(wound, ischemia, and foot infection). 
A separate grade is given to the wound 
(the presence and depth of ulcer), 
ischemia (based on ABI, toe pressure, 
or transcutaneous oxygen pressure 
(TcPO2)), and infection (local to systemic). 
The three grades are combined to give a 
risk of amputation and estimated benefit 
of revascularization. WIfI is robust to 
account for several factors in PAD but 
it has not validated in many research 
studies.54
Management for DFU
Diabetic foot ulcer is a difficult to 
heal ulcer. The pathogenesis of DFU 
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and the results of the initial evaluation 
of the patient should be considered in 
planning of the management strategies. 
Peripheral neuropathy, foot deformity, 
PAD, frequent minor trauma, and 
infection need to be well managed. 
Glycemic control must be achieved, and 
standard wound care must be delivered 
to the patients. Standard wound care 
includes local debridement, wound 
offloading, wound moisture balance with 
appropriate dressings, control of edema, 
and control of infection. Education about 
preventive foot care should be given to 
the patients and their families.1,55
A multidisciplinary team, consist of 
individuals who have the skills (medical, 
surgical, podiatric, nursing, and orthotic), 
should be involved in DFUs management. 
This multidisciplinary team has been 
successfully implemented in different 
centers from various countries, resulting 
in a substantial decrease in amputation 
rate.2,50
Glycemic control
Glycemic control, as reflected by 
hemoglobin A1c (HbA1c) measurement, 
is a must for DFU patients. HbA1c 
is inversely related to healing rate, 
particularly in patients with peripheral 
neuropathy and PAD.56 Early tight 
control of blood glucose is targeted. 
The recommended adequate glycemic 
control is HbA1c < 7%.
55
Local debridement
Removal of necrotic tissues as well 
as foreign and infected objects from an 
ulcer by debridement is the first critical 
step in the wound care, especially in the 
control of deep infection.2,52 Debridement 
can decrease bacterial counts, facilitate 
wound drainage, and reduce pressure 
on the ulcer. Evaluation of the wound 
bed and wound closure are facilitated 
by debridement (FIGURE 1). Adequate 
debridement decreases the possibility of 
limb amputation.57
A B
FIGURE 1. Necrotic tissue covers a diabetic foot ulcer on the plantar pedis before 
debridement (A). A deep ulcer penetrating to the bone and joint is 
visible after debridement (B) (photographs courtesy of dr. Daniel 
Ardian Soeselo, Sp.B) 
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There are several techniques of 
debridement including surgical or sharp, 
mechanical, enzymatic, biological, and 
autolytic.2,57 Two systematic reviews 
and a literature review discussing 
debridement methods had been 
published recently.11,57,58 They found that 
available literature supported putative 
benefits of surgical and biological 
debridement. However, the quality of 
comparative effectiveness evidence 
between the debridement methods was 
low. Consequently, the need for and 
choice of technique of debridement 
are based on the available expertise 
and supplies, patient tolerance and 
preference, the clinical context (such as 
level of perfusion and extent of tissue 
loss), and cost-effectiveness.55,57,58 It 
should be remembered that the aim 
of debridement is not only to achieve 
wound closure, but also to maintain 
ambulation. In situations without a 
limb-threatening infection, surgical 
debridement should be done after the 
blood supply to the wound/extremity is 
optimized, to ensure that viable tissue 
is not removed.2 If new necrotic tissue 
continues to form, repeated surgical 
debridement should be conducted.57
Offloading
Offloading, or pressure modulation, 
is the cornerstone management for 
neuropathic DFUs and ulcers with 
increased biomechanical stress.50,57 The 
aim of offloading is to treat the foot ulcer 
and to maintain the ability of the patient 
to walk. A threshold of a peak pressure 
< 200 KPa has to be achieved by the 
offloading system to allow the ulcer to 
heal.2 
There are many offloading 
modalities nowadays, divided into non-
surgical and surgical. The non-surgical 
offloading modalities include soft and 
shock absorbing materials, custom 
molding, forefoot or heel offloading 
shoes, rocker-bottom shoes, casts, 
walkers, crutches, and wheelchair. The 
example of surgical modalities is Achilles 
Tendon-Lengthening (ATL), which is 
performed to reduce plantar pressure 
because of foot deformities.2,50 Patient 
physical characteristics and compliance 
in conjunction with the location and 
severity of the ulcer determine the 
choice of the modalities.57 Total contact 
casting and irremovable cast walkers 
show benefits in  the treatment of DFUs, 
although based on low-quality evidence.59 
Another literature review assign grade A 
recommendation to offloading and grade 
B recommendation to ATL.60 A removable 
cast walker is suggested as an alternative 
for patients who need frequent dressing 
changes.55 Specific therapeutic footwear 
with pressure-relieving insoles is 
recommended for high-risk patients 
with healed DFU to reduce relapse.55,59
Wound dressing
Dressing that provides moisture 
balance of the wound, sequestrates 
protease, stimulates growth factor 
stimulation, has an antimicrobial 
activity, permeable for oxygen to pass 
through the wound, and promotes 
autolytic debridement is the ideal 
dressing for DFU. Nowadays there is no 
single dressing which can fulfill all those 
requirements.57 Dressing that maintains 
a moist wound bed, controls exudate, 
and avoids maceration of the intact skin 
surrounding the wound is recommended 
for DFU.55 
Films, hydrogels, hydrocolloids, 
alginates, foams, and silver-impregnated 
are novel dressings used over the last 
decade for DFUs.57,61 Cause of the DFU, 
the location and depth of the wound, 
the amount of scar or slough, exudates, 
and condition of the wound boundaries, 
the presence of infection and pain, 
requirement for adhesiveness, and 
conformability of the dressing should 
determine the selection of the dressing.57 
However, a significant advantage of a 
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certain wound dressing in the healing 
rate of DFUs can not be concluded based 
on existing data as yet.57,61 Simple gauze 
and saline solution alone still appears to 
be sufficient for most patients.52 
Treatment of peripheral edema
Peripheral edema on the foot/leg of 
DFU patients should be evaluated. There 
are several factors that can cause the 
edema, such as congestive heart failure, 
nephropathy, infection and hydrostatic/
neuropathic edema. External 
compression therapy, intermittent 
compression pumps, and diuretics are 
examples of treatment for peripheral 
edema. However, the most important 
thing to note is that peripheral edema in 
DFU patients should be treated according 
to the causative factors.2,50
Treatment of infection
Duration, extent and severity of 
infection and knowledge of the local 
microbial epidemiology dictate the 
empirical antibiotic regimen and mode 
of antibiotic administration.2,52 Patients 
with acute mild-to-moderate infections 
and have not received antibiotic therapy 
may be sufficient if treated with antibiotic 
against aerobic Gram-positive cocci. 
Broad spectrum empirical therapy is not 
routinely required for chronic ulcers 
with polymicrobial flora, but is indicated 
for moderate to severe infections. 
Empirical parenteral broad-spectrum 
antibiotic therapy aimed at Gram-
positive and Gram-negative bacteria, 
including anaerobes, may be given for 
deep and limb-threatening infection. 
Definitive therapy should be based on 
culture results and susceptibility data 
and clinical response to the empirical 
regimen. Antibiotic therapy should be 
continued until the infection has been 
controlled but not necessarily until the 
wound has healed.2,12,50,52
Infections accompanied by a 
deep abscess, osteomyelitis, crepitus, 
substantial necrosis or gangrene, or 
necrotizing fasciitis need immediate 
surgical consultation. Urgent incision 
and drainage of an abscess and radical 
debridement of all infected, non-viable 
necrotic tissue are the most important 
steps in controlling deep infection. The 
debridement should be done first and in 
the case of ischemia, revascularization 
thereafter.2,12,52
Surgery
Surgery for DFUs includes 
nonvascular foot surgery, vascular foot 
surgery, and amputation. Nonvascular 
foot surgery aims to correct foot 
deformities that increase pressure 
(offload), for example surgical excision 
of ulcers, arthroplasties, metatarsal 
head resections and ATL.2,57 Vascular 
foot surgery (revascularization) is 
indicated to relieve symptoms of limb-
threatening ischemia. These symptoms 
include ischemic pain, ischemic ulcers, 
and gangrene. Achieving at least one 
open infrapopliteal artery, preferably 
the artery that supplies the anatomical 
region of the ulcer, is the goal of 
revascularization.2 Amputation is the last 
resort of an urgent or curative surgery 
to be considered after all other salvage 
techniques has been attempted, and the 
patient must give informed consent.57 
Adjunctive therapies
Adjunctive wound therapy options 
are recommended for DFUs that fail to 
show >50% wound area reduction after 
a 4 weeks of standard wound therapy.55 
These adjunctive therapies include 
negative pressure wound therapy 
(NPWT), biologics (PDGF, living cellular 
therapy, extracellular matrix products, 
amniotic membrane products), and 
hyperbaric oxygen therapy (HBOT). 
A systematic review to study the 
effectiveness of interventions to enhance 
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healing of DFUs found that there is still 
little published evidence to justify the 
use of newer therapies, with the possible 
exception of NPWT in post-operative 
wounds.11 Choice of adjuvant therapy is 
based on clinical findings, availability of 
therapy, and cost-effectiveness. Vascular 
status, infection control, and offloading 
is recommended to be optimized before 
initiation of adjunctive wound therapy.55 
Education
Educating diabetic patients and 
families on foot self-management is 
considered to be the basis of preventing 
DFUs and reducing the chance of 
recurrences. Up to 50% of DFUs can 
be prevented by effective education. 
Diabetic patients with/without DFUs 
should be educated about risk factors 
and the significance of foot care, 
including self-inspection, examining 
the temperature of the foot, appropriate 
daily foot hygiene maintenance, use 
of suitable footwear, and blood sugar 
control. Several education sessions over 
time, using a mixture of methods, should 
be provided. Whether the diabetic 
patient has understood the messages, is 
motivated to act, and has sufficient self-
care skills are essential to evaluate.50,55,57 
CONCLUSION
The pathogenesis of DFU is very 
complex. Diabetic patients are vulnerable 
to develop foot ulcers due to peripheral 
neuropathy, foot deformity, minor foot 
trauma, and peripheral arterial disease. 
Derangements of neuropeptides, 
hypoxia, hyperglycemia, and infection 
contribute to the chronicity of DFUs. 
The patient as a whole, the 
characteristics of the ulcer, the presence 
of neuropathy, the vascular insufficiency, 
and the presence of infection should 
be evaluated at initial evaluation of 
DFU patients. The ulcer then classified 
according to the classification system to 
alert clinicians about the severity of the 
ulcer and the risk of amputation, so that 
a suitable management strategies can be 
set.
In the management of DFUs, blood 
sugar must be under control and standard 
wound care must be delivered to each 
patient. Standard wound care includes 
local wound debridement, wound 
offloading, wound moisture balance 
with appropriate dressings, control of 
edema, and control of infection. Blood 
supply to the wound/extremity should be 
adequate. Education about preventive 
foot care should be given to the patients 
and their families. A multidisciplinary 
team should be involved in DFUs 
management.
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